Evidence map›Paper›PMID 37787852›Full record

SynthesisEuropean journal of clinical pharmacology2023

Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis.

Miao Zhang, Bingchen Lang, Hailong Li, Liang Huang, Linan Zeng, Zhi-Jun Jia, Guo Cheng, Yu Zhu, Lingli Zhang

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in European journal of clinical pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Lifestyle and Environment Aspects Challenging Kidney Health.Kidney & blood pressure research · 2026
    Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Miao Zhang *Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Bingchen Lang *Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Hailong LiDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Liang HuangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Linan ZengDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Zhi-Jun JiaDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China.
Guo ChengKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China.
Yu ZhuKey Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University, Chengdu, China. zhuyu_wj@163.com.
Lingli ZhangDepartment of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China. zhanglingli@scu.edu.cn.
National Medical Products Administration · CNSichuan University · CNWest China Second University Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo comprehensively summarize the incidence and risk factors of drug-induced kidney injury (DIKI) in children.

methodsWe systematically searched seven databases from inception to November 2022. Two independent reviewers selected studies, extracted data, and assessed the risk of bias. Meta-analyses were conducted to quantify the incidence and risk factors of DIKI in children.

resultsA total of 69 studies comprising 195,894 pediatric patients were included. Overall, the incidence of DIKI in children was 18.2% (95%CI: 16.4%-20.1%). The incidence of DIKI in critically ill children (19.6%, 95%CI: 15.9%-23.3%) was higher than that in non-critically ill children (16.1%, 95%CI: 12.9%-19.4%). Moreover, the risk factors for DIKI in children were intensive care unit (ICU) admission (OR = 1.59, 95% CI: 1.42-1.78, P = 0.000), treatment days (OR = 1.04, 95% CI: 1.03-1.05, P = 0.000), surgical intervention (OR = 1.43, 95% CI: 1.00-2.02, P = 0.048), infection (OR = 2.30, 95% CI: 1.44-3.66, P = 0.000), patent ductus arteriosus (OR = 4.78, 95% CI: 1.82-12.57, P = 0.002), chronic kidney disease (OR = 2.78, 95% CI: 1.92-4.02, P = 0.000), combination with antibacterial agents (OR = 1.98, 95% CI: 1.54-2.55, P = 0.000), diuretics (OR = 1.97, 95% CI: 1.51-2.56, P = 0.000), combination with antiviral agents (OR = 1.50, 95% CI: 1.11-2.04, P = 0.008), combination with non-steroidal anti-inflammatory drugs (OR = 1.79, 95% CI: 1.40-2.28, P = 0.000), and combination with immunosuppressive agents (OR = 2.84, 95% CI: 1.47-5.47, P = 0.002).

conclusionThe incidence of DIKI in children is high, especially in critically ill children. Identifying high-risk groups and determining safer treatments is critical to reducing the incidence of DIKI in children. In clinical practice, clinicians should adjust medication regimens for high-risk pediatric groups, such as ICU admission, some underlying diseases, combination with nephrotoxic drugs, etc., and regularly evaluate kidney function throughout treatment.

Indexed as

Critical IllnessKidney DiseasesChildHumansIncidenceIntensive Care UnitsKidneyRisk FactorsChildrenDrug-induced kidney injuryIncidenceRisk factorsSystematic review

Identifiers

PMID37787852
OpenAlexW4387296279

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.